Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2022

View Archived Issues

CD14 associated with poor cognitive function in survivors of testicular germ-cell tumors

Lipidated IL-22 ameliorates colon inflammation in preclinical colitis model

Study shows how gut-derived metabolites enter the brain and affect behavior

IBD-3540, a novel gut-restricted GCPII inhibitor with oral preclinical activity in models of colitis

Shaanxi Synthetic Pharmaceutical divulges new antiarthritic drugs

Guangzhou Henovcom Bioscience discloses new antivirals

T2YC presents new integrin modulators

IFM Due synthesizes new hSTING antagonists

Institute of Medicinal Biotechnology presents new androgen receptor antagonists

Targeting of CRYAB with 25-hydroxycholesterol induces kills senescent cells in vitro and in vivo

AU-011 shows promising binding and tumor distribution in models of urothelial neoplasia

DNA methylation mediated by METTL3-METTL14 complex is largely restricted by structured RNA elements

CD70 identified as promising therapeutic target in advanced RCC

Moderna announces new mRNA vaccine candidates for HSV, VZV and cancer

SIGMAR1 targeting ameliorates preclinical Wolfram syndrome symptoms

GR-3027 reverses neuroinflammation in rat model of hyperammonemia

"Twin study" of sorts brings insight into arthritis microbiome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...